Anecdotal reports of the use of P57 in humans show that it significantly reduces appetite, food intake and body weight. Considerable work has been undertaken to fractionate this plant material and a number of compounds have been isolated from the mixture, some of which have biological activity. The mechanism of action of P57 and its active constituents is currently under investigation. Additional pharmacological properties have recently been established.
Efficacy has been established with a profound weight loss and a good emergent safety profile. Considerable progress has been achieved with this project. Phase I clinical development continues alongside an extensive research program. In parallel to these activities, additional plantations for the plant material have been established world-wide in collaboration with the CSIR and Pfizer and a clinical supplies unit, dedicated to the manufacture of the material, has been opened in South Africa.

1 Comments